Frontier Medicines vs Karius
Side-by-side comparison of AI visibility scores, market position, and capabilities
Precision Oncology & Undruggable Target Drug Discovery
Frontier Medicines is a precision medicine biotech targeting previously undruggable disease-causing proteins using chemoproteomics and covalent chemistry platforms; raised $350M+ in funding including a $257M Series C in 2022;
About
Frontier Medicines is a South San Francisco-based biopharmaceutical company founded in 2018 by Ulf Bhatt and Jonathan Ogg, with scientific founding involvement from leading chemoproteomics researchers. The company's core focus is developing precision medicines against proteins that have historically been considered "undruggable" — disease-causing targets where conventional drug discovery approaches have failed due to the protein's structure, chemistry, or biology. Frontier addresses this challenge through two proprietary technology platforms: the Frontier platform (chemoproteomics-based covalent chemistry for small molecule drug discovery) and the AutoTAC platform (targeted protein degradation using autophagy pathways).
Karius raised $409M total including a $100M Series C in May 2024; its genomic blood test detects 1,000+ pathogens at 400+ U.S. hospitals; launched Karius Focus BAL for pneumonia in April 2025.
About
Karius is a Redwood City, CA-based life sciences company founded in 2014 that developed the Karius Test — a single blood draw that uses next-generation sequencing and AI to detect over 1,000 pathogens (bacteria, fungi, viruses, parasites) in seriously ill patients. The test is used when conventional cultures and targeted diagnostics fail, providing clinicians at transplant centers, children''s hospitals, and ICUs with a comprehensive pathogen report within 24 hours.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.